Page last updated: 2024-11-12
fi-700
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
FI-700: FLT3 inhibitor that selectively suppresses the growth of leukemia cells with FLT3 mutations; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11517444 |
| CHEMBL ID | 486332 |
| MeSH ID | M0514848 |
Synonyms (9)
| Synonym |
|---|
| CHEMBL486332 |
| 866883-79-6 |
| n548ap3gtf , |
| fi-700 |
| 2,4-pyrimidinediamine, 5-(5-(1-piperazinylmethyl)-1,3,4-oxadiazol-2-yl)-n4-propyl-n2-(2-(4-pyridinyl)ethyl)- |
| unii-n548ap3gtf |
| 5-(5-(piperazin-1-ylmethyl)-1,3,4-oxadiazol-2-yl)-n4-propyl-n2-(2-(pyridin-4-yl)ethyl)pyrimidine-2,4-diamine |
| Q27284565 |
| 5-[5-(piperazin-1-ylmethyl)-1,3,4-oxadiazol-2-yl]-4-n-propyl-2-n-(2-pyridin-4-ylethyl)pyrimidine-2,4-diamine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID344776 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal regressive tumor volume ratio at 200 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344782 | Antitumor activity against human MOLM13 cells xenografted in po dosed SCID mouse assessed as tumor volume ratio administered bid for 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344768 | Antiproliferative activity against human HMC1 cells expressing FLT3-delta599 mutant after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344775 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal regressive tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 4 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344779 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 50 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344774 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344767 | Metabolic stability in human liver microsomes assessed as intrinsic clearance | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344781 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 200 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344773 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as tumor volume ratio at 200 mg/kg, po bid treated for 5 days measured after 10 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344772 | Antitumor activity against human MOLM13 cells xenografted in SCID mouse assessed as minimal tumor volume ratio at 100 mg/kg, po bid treated for 5 days measured after 7 days relative to control | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344769 | Antiproliferative activity against human HMC1 cells expressing FLT-D835Y mutant after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344784 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as body weight loss at 200 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344780 | Toxicity to human MOLM13 cells xenografted SCID mouse assessed as mortality at 100 mg/kg, po bid after 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344766 | Antiproliferative activity against human MOLM13 cells after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344783 | Antitumor activity against human MOLM13 cells xenografted in po dosed SCID mouse assessed as regression tumor volume ratio administered bid for 5 days | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| AID344770 | Antiproliferative activity against human ML1 cells after 72 hrs by WST-1 assay | 2008 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20 | Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 48.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.30) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||